title: Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.
abstract: Preventing tumor neovascularisation is one of the strategies recently developed to limit the dissemination of cancer cells and apparition of metastases. Although these approaches could improve the existing treatments, a number of unexpected negative effects have been reported, mainly linked to the hypoxic condition and the subsequent induction of the pro-oncogenic hypoxia inducible factor(s) resulting from cancer cells' oxygen starvation. Here, we checked in vivo on colon cancer cells an alternative approach. It is based on treatment with myo-inositol trispyrophosphate (ITPP), a molecule that leads to increased oxygenation of tumors. We provide evidence that ITPP increases the survival of mice in a model of carcinomatosis of human colon cancer cells implanted into the peritoneal cavity. ITPP also reduced the growth of subcutaneous colon cancer cells xenografted in nu/nu mice. In the subcutaneous tumors, ITPP stimulated the expression of the homeobox gene Cdx2 that is crucial for intestinal differentiation and that also has an anti-tumoral function. On this basis, human colon cancer cells were cultured in vitro in hypoxic conditions. Hypoxia was shown to decrease the level of Cdx2 protein, mRNA and the activity of the Cdx2 promoter. This decline was unrelated to the activation of HIF1α and HIF2α by hypoxia. However, it resulted from the activation of a phosphatidylinositol 3-kinases-like mitogen-activated protein kinase pathway, as assessed by the fact that LY294002 and U0126 restored high Cdx2 expression in hypoxia. Corroborating these results, U0126 recapitulated the increase of Cdx2 triggered by ITPP in subcutaneous colon tumor xenografts. The present study provides evidence that a chemical compound that increases oxygen pressure can antagonize the hypoxic setting and reduce the growth of human colon tumors implanted in nu/nu mice.
authors.affiliation: INSERM U682, Strasbourg, France.
authors.forename: L
authors.initials: L
authors.lastname: Derbal-Wolfrom
authors.forename: E
authors.initials: E
authors.lastname: Pencreach
authors.forename: T
authors.initials: T
authors.lastname: Saandi
authors.forename: M
authors.initials: M
authors.lastname: Aprahamian
authors.forename: E
authors.initials: E
authors.lastname: Martin
authors.forename: R
authors.initials: R
authors.lastname: Greferath
authors.forename: E
authors.initials: E
authors.lastname: Tufa
authors.forename: P
authors.initials: P
authors.lastname: Choquet
authors.forename: J-M
authors.initials: JM
authors.lastname: Lehn
authors.forename: C
authors.initials: C
authors.lastname: Nicolau
authors.forename: I
authors.initials: I
authors.lastname: Duluc
authors.forename: J-N
authors.initials: JN
authors.lastname: Freund
mesh_terms: D000818:Animals; D000071616:CDX2 Transcription Factor; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000235:genetics* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D004195:Disease Models, Animal; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D000860:Hypoxia; D007295:Inositol Phosphates / Q000008:administration & dosage / Q000494:pharmacology*; D020935:MAP Kinase Signaling System; D051379:Mice; D010101:Oxygen Consumption; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D000071616:CDX2 Transcription Factor; C491270:CDX2 protein, human; D018398:Homeodomain Proteins; D007295:Inositol Phosphates; C516441:inositol trispyrophosphate; D051057:Proto-Oncogene Proteins c-akt